hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for an oral formulation of its weight loss therapy Wegovy (semaglutide) for review.
Subject to FDA approval of the company's new drug application (NDA), the